A VEGF-A splice variant defective for heparan sulfate and neuropilin-1 binding shows attenuated signaling through VEGFR-2.
about
Extracellular regulation of VEGF: isoforms, proteolysis, and vascular patterning.An unexpected tail of VEGF and PlGF in pre-eclampsiaVascular Endothelial Growth Factor-A165b Is Protective and Restores Endothelial Glycocalyx in Diabetic NephropathyStructural basis for ligand and heparin binding to neuropilin B domainsStructural determinants of growth factor binding and specificity by VEGF receptor 2Serine-arginine protein kinase 1 (SRPK1) inhibition as a potential novel targeted therapeutic strategy in prostate cancerA multiscale computational model predicts distribution of anti-angiogenic isoform VEGF165b in peripheral arterial disease in human and mouseOverexpression of VEGF165b in podocytes reduces glomerular permeability.Recombinant human VEGF165b inhibits experimental choroidal neovascularizationTherapeutic potential of manipulating VEGF splice isoforms in oncologyThe anti-angiogenic isoforms of VEGF in health and disease.VEGF in the lung: a role for novel isoformsProgrammed translational readthrough generates antiangiogenic VEGF-AxVEGF-A165b is cytoprotective and antiangiogenic in the retinaThe role of VEGF-A165b in trophoblast survival.Molecular diversity of VEGF-A as a regulator of its biological activity.Do anti-angiogenic VEGF (VEGFxxxb) isoforms exist? A cautionary taleBorrelidin modulates the alternative splicing of VEGF in favour of anti-angiogenic isoformsDevelopment and strategies of VEGFR-2/KDR inhibitors.New Insights into VEGF-A Alternative Splicing: Key Regulatory Switching in the Pathological ProcessAn antiangiogenic isoform of VEGF-A contributes to impaired vascularization in peripheral artery diseaseThe carboxyl terminus of VEGF-A is a potential target for anti-angiogenic therapyRelevance of VEGF and nephrin expression in glomerular diseases.Alternative RNA splicing and cancerBalance of pro- versus anti-angiogenic splice isoforms of vascular endothelial growth factor as a regulator of neuroblastoma growth.VEGF111b, a C-terminal splice variant of VEGF-A and induced by mitomycin C, inhibits ovarian cancer growth.Ovarian VEGF(165)b expression regulates follicular development, corpus luteum function and fertilityVEGFA splicing: divergent isoforms regulate spermatogonial stem cell maintenance.The role of VEGF 165b in pathophysiologyThe endogenous anti-angiogenic VEGF isoform, VEGF165b inhibits human tumour growth in mice.VEGF receptors and neuropilins are expressed in the urothelial and neuronal cells in normal mouse urinary bladder and are upregulated in inflammation.Inhibition of tumor cell migration by LD22-4, an N-terminal fragment of 24-kDa FGF2, is mediated by Neuropilin 1Recombinant human VEGF165b protein is an effective anti-cancer agent in mice.Urothelial expression of neuropilins and VEGF receptors in control and interstitial cystitis patientsVEGF-A splicing: the key to anti-angiogenic therapeutics?VEGF-A165b is an endogenous neuroprotective splice isoform of vascular endothelial growth factor A in vivo and in vitro.VEGF-A mRNA processing, stability and translation: a paradigm for intricate regulation of gene expression at the post-transcriptional level.HTLV-1 uses HSPG and neuropilin-1 for entry by molecular mimicry of VEGF165VEGF(121)b, a new member of the VEGF(xxx)b family of VEGF-A splice isoforms, inhibits neovascularisation and tumour growth in vivoBrittlestars contain highly sulfated chondroitin sulfates/dermatan sulfates that promote fibroblast growth factor 2-induced cell signaling.
P2860
Q27000351-7399043D-8804-42EE-9CEC-00133A70F1D4Q27000996-85B96A17-DD00-441F-B2D6-BD433029E007Q27342809-5FF22865-5040-414D-A19E-3EB73984A680Q27644336-95CEBED4-4F88-4C5B-AB3B-AE60F8C12D05Q27659686-28CCEDE4-D45B-47F9-AD54-5FC746DD7E9DQ28251240-168B9A71-B41D-4585-8CCF-0D8AC4C73391Q30275400-539C1149-CE7B-4B0C-AE9A-469E5F9C952FQ30497786-109EC77B-605D-4E56-8187-15FD4BECCC1EQ33541827-181DCB9E-E788-4C0C-8123-7181B1BF54FAQ33888458-B257B125-DE83-420C-8857-BA52079FA8D4Q33901839-6B0E36EE-D8E2-4571-B5BF-2096BCA61D27Q33916926-B2C801F1-685B-443B-9DBA-A92BB9DE042CQ33959462-F6527DD3-EA18-4C44-A00C-3878C6922C90Q34022623-4A3E23F8-1D00-4DAA-82DE-585C2A52E84AQ34084917-9172904E-CB79-4C76-9DDA-2A1566DAEDC6Q34089123-C2D9D277-E04A-4DCE-B7BC-5118F9E23B34Q34261539-38038F5B-A65E-4707-A166-D9C8D48F8F0EQ34347768-0678A861-CD09-4984-8430-0980522A0820Q34436101-5EBC40CA-8C26-49A4-9F74-19E9CDB70DC5Q34474159-D9139BCA-5F7E-4561-BDA7-6C5BE7C5CD5BQ34641120-E1D0915C-B2B2-47FA-9C41-5F99FA7EA544Q34792239-C565302B-48D9-49BC-A36F-BB9D8A24E503Q35131059-B620B563-202C-493B-B51E-EB3C56DA18D5Q35589667-2FA33D85-6642-4362-A65E-DD14495F462CQ35780472-AA7DCE6F-96C7-4247-9B3B-832F31EA3B31Q35780939-AC7B24F1-D561-4FFA-BDCC-664EE8E037FCQ35885946-1B422F24-6621-44CC-9085-3803E484F277Q36436720-81A07A28-9B9A-4376-9E84-E4AEEFB1C393Q36542093-D5D60CD5-7978-4371-8DEC-1DD11276D55EQ36608586-235D523D-9169-461C-811F-4AD7CA1F6F77Q36807118-54122095-B4BF-4B4D-9847-61CA07A66459Q36906713-08003D7C-E57E-4268-8C88-B8E05770A7DFQ36932464-8BD3BF36-CEC8-4B14-AA61-38D3E48E3AAEQ37018478-74BAF6AA-2943-4D77-8C75-7E4CA0F2FA99Q37035757-55FACBCC-462D-40CC-AD7B-2E9628D5A373Q37149053-6CE3352D-89C2-4843-86E6-589F042215AEQ37197773-C1EA2F34-C685-4FC0-90C7-9B004765ECE6Q37201969-14C20441-87EF-4723-8CB8-A2EE7D3BB692Q37400534-28F1217B-7166-485A-8557-402A99339FDEQ37532995-5420E4D8-7B91-4888-B254-67F4BCAB75C0
P2860
A VEGF-A splice variant defective for heparan sulfate and neuropilin-1 binding shows attenuated signaling through VEGFR-2.
description
2006 nî lūn-bûn
@nan
2006 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
A VEGF-A splice variant defect ...... ted signaling through VEGFR-2.
@ast
A VEGF-A splice variant defect ...... ted signaling through VEGFR-2.
@en
A VEGF-A splice variant defect ...... ted signaling through VEGFR-2.
@nl
type
label
A VEGF-A splice variant defect ...... ted signaling through VEGFR-2.
@ast
A VEGF-A splice variant defect ...... ted signaling through VEGFR-2.
@en
A VEGF-A splice variant defect ...... ted signaling through VEGFR-2.
@nl
prefLabel
A VEGF-A splice variant defect ...... ted signaling through VEGFR-2.
@ast
A VEGF-A splice variant defect ...... ted signaling through VEGFR-2.
@en
A VEGF-A splice variant defect ...... ted signaling through VEGFR-2.
@nl
P2093
P1476
A VEGF-A splice variant defect ...... ted signaling through VEGFR-2.
@en
P2093
Ballmer-Hofer K
Cariolato L
Cébe Suarez S
Hoffmann U
P2888
P304
P356
10.1007/S00018-006-6254-9
P577
2006-09-01T00:00:00Z